Compare Nuvalent Inc (NUVL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Summit Therapeutics Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: Nuvalent Inc and Summit Therapeutics Inc are close in size by market cap, and Nuvalent Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| NUVL | SMMT | |
|---|---|---|
Market Cap | $9.81B | $10.48B |
Sector | Technology | Health |
52-Week High | $123.96 | $29.32 |
52-Week Low | $72.16 | $13.05 |
Enterprise Value | $8.52B | $9.90B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
